Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell?

Hims & Hers (HIMS) stock gained 3.8% over the past three months, outperforming the market, driven by strong Q2 2025 online revenue growth, subscriber additions, and new men's health offerings, with robust revenue guidance for Q3 and full-year 2025. However, the company faces significant operational complexities and regulatory risks, including contracting gross margins from rising product costs, compliance burdens from international expansion and new product lines like compounded GLP-1s (which face FDA restrictions), and potential dilution from convertible debt. Despite strong subscriber retention and new hormonal health verticals, Zacks maintains a "Sell" rating (Rank #4) due to these escalating risks and a 6.3% downward revision in 2025 EPS estimates, advising caution despite its growth potential.

Analysis

Hims & Hers (HIMS) has demonstrated recent stock outperformance, gaining 3.8% over the past three months, surpassing the broader market and peers like Teladoc Health (TDOC) and American Well (AMWL). This momentum is supported by robust Q2 2025 results, including strong online revenue growth, increased subscribers, and an expanding operating margin, alongside the launch of new men's health offerings. The company projects significant revenue growth for Q3 2025 (42-47% YoY) and the full year (56-63% from 2024), with consensus estimates aligning closely.

Despite top-line strength, HIMS faces notable operational and financial pressures. Q2 2025 gross margin contracted due to rising product costs and weak Wholesale revenues. Aggressive international expansion, including the ZAVA acquisition and planned Canadian launch, introduces significant compliance burdens and integration challenges, with the ZAVA deal not expected to be accretive until 2026.

Further concerns arise from the company's reliance on an $870 million convertible debt issue, posing potential dilution risk given the $70.67 conversion price, especially as capital deployment for acquisitions lacks definitive agreements. Regulatory headwinds are also intensifying, particularly the FDA's February 2025 resolution on semaglutide shortages, which restricts compounded GLP-1 sales—a key growth driver—and introduces new compliance obligations for peptide manufacturing and lab testing. These factors contribute to a 6.3% downward revision in 2025 EPS estimates.

While HIMS boasts a scaling subscription model with high retention and is expanding into new hormonal health verticals, the escalating regulatory and operational complexities overshadow its growth narrative. The company's forward 12-month P/S of 4.6x, while below the industry average of 5.9x, is significantly higher than its three-year median of 2.5x, suggesting elevated growth expectations. This confluence of factors has led to a Zacks Rank #4 (Sell) rating, advising caution despite the company's growth potential.

Key Decisions for Investors

• Investors should closely monitor Hims & Hers' upcoming Q3 2025 earnings report for clarity on gross margin trends and the impact of rising product costs, given the recent contraction and weak Wholesale sales.
• Evaluate the company's progress on international expansion integration and regulatory compliance, particularly regarding the FDA's restrictions on compounded GLP-1 products and new obligations for peptide manufacturing, as these pose significant revenue and operational risks.
• Consider the potential for dilution from the $870 million convertible debt and management's capital deployment efficiency, especially with no definitive acquisition agreements in place, which could impact long-term shareholder value.